ZA9510865B - Stable 2-chloro-2'-deoxyadenosine formulations - Google Patents

Stable 2-chloro-2'-deoxyadenosine formulations

Info

Publication number
ZA9510865B
ZA9510865B ZA9510865A ZA9510865A ZA9510865B ZA 9510865 B ZA9510865 B ZA 9510865B ZA 9510865 A ZA9510865 A ZA 9510865A ZA 9510865 A ZA9510865 A ZA 9510865A ZA 9510865 B ZA9510865 B ZA 9510865B
Authority
ZA
South Africa
Prior art keywords
formulations
deoxyadenosine
chloro
stable
cda
Prior art date
Application number
ZA9510865A
Other languages
English (en)
Inventor
Michael Bornstein
Kevin Francis Long
Rosemary Rozman
Hsiao Yung Guh
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of ZA9510865B publication Critical patent/ZA9510865B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
ZA9510865A 1994-12-21 1995-12-20 Stable 2-chloro-2'-deoxyadenosine formulations ZA9510865B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/362,106 US5641757A (en) 1994-12-21 1994-12-21 Stable 2-chloro-2'-deoxyadenosine formulations

Publications (1)

Publication Number Publication Date
ZA9510865B true ZA9510865B (en) 1997-06-20

Family

ID=23424722

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9510865A ZA9510865B (en) 1994-12-21 1995-12-20 Stable 2-chloro-2'-deoxyadenosine formulations

Country Status (16)

Country Link
US (1) US5641757A (ja)
EP (1) EP0799046B1 (ja)
JP (1) JP2001520627A (ja)
AT (1) ATE218351T1 (ja)
AU (1) AU709785B2 (ja)
CZ (1) CZ194197A3 (ja)
DE (1) DE69526970T2 (ja)
DK (1) DK0799046T3 (ja)
ES (1) ES2177677T3 (ja)
HU (1) HU220628B1 (ja)
IL (1) IL116468A0 (ja)
PL (1) PL320918A1 (ja)
PT (1) PT799046E (ja)
SI (1) SI0799046T1 (ja)
WO (1) WO1996019229A1 (ja)
ZA (1) ZA9510865B (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
FR2862872A1 (fr) * 2003-12-02 2005-06-03 Palbian Snc Composition a l'etat aqueux pour l'application perfusable d'un principe actif, notamment pharmacologique tel que le paracetamol.
AU2005318190B2 (en) 2004-12-22 2010-11-25 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
EA020805B1 (ru) 2006-05-24 2015-01-30 Мерк Сероно С.А. Применение комбинации кладрибина и бета-интерферона для лечения рассеянного склероза
JP2012176899A (ja) * 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CA3083328A1 (en) 2017-11-24 2019-05-31 Merck Patent Gmbh Cladribine regimen for use intreating progressive forms of multiple sclerosis
KR20230066402A (ko) 2020-09-10 2023-05-15 메르크 파텐트 게엠베하 자가면역 장애의 치료를 위한 신규 치료 용법
CA3209648A1 (en) 2021-03-03 2022-09-09 Ursula BOSCHERT SHAFAATIAN Improved treatment methods using dmds for the treatment of autoimmune diseases, and biomarker for predicting and/or optimising said treatment methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US4719295A (en) * 1985-12-31 1988-01-12 Warner-Lambert Company Compound 2-iodo-2'-deoxyadenosine
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) * 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
AU678557B2 (en) * 1992-05-19 1997-06-05 Scripps Research Institute, The Use of 2-halo adenine derivatives as therapeutic agents against chronic myelogenous leukemia

Also Published As

Publication number Publication date
WO1996019229A1 (en) 1996-06-27
DE69526970T2 (de) 2003-01-09
PL320918A1 (en) 1997-11-10
SI0799046T1 (en) 2002-10-31
DE69526970D1 (de) 2002-07-11
HU220628B1 (hu) 2002-03-28
IL116468A0 (en) 1996-03-31
JP2001520627A (ja) 2001-10-30
PT799046E (pt) 2002-10-31
ES2177677T3 (es) 2002-12-16
EP0799046B1 (en) 2002-06-05
DK0799046T3 (da) 2002-09-16
ATE218351T1 (de) 2002-06-15
EP0799046A1 (en) 1997-10-08
AU4422996A (en) 1996-07-10
US5641757A (en) 1997-06-24
MX9704731A (es) 1997-10-31
AU709785B2 (en) 1999-09-09
HUP9900774A2 (en) 2001-05-28
CZ194197A3 (en) 1997-10-15

Similar Documents

Publication Publication Date Title
ZA9510865B (en) Stable 2-chloro-2'-deoxyadenosine formulations
BR9713866A (pt) Composição farmacéutica
MY121360A (en) Clear cleansing detergent systems.
EP0841936A4 (en) CONJUGATION-STABILIZED THERAPEUTIC AGENT COMPOSITIONS, ADDITIONAL FORMULATIONS AND DIAGNOSTICS
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
ATE257014T1 (de) Lichtbilderzeugungskontrastmitteln
DE69638351D1 (de) Sowie zur resektion des distalen und vorderen femurs
PL322175A1 (en) Oral pharmaceutic administration forms containing the protonic pump inhibitor and either an acid neutralising agent or alginate
ITTO950085V0 (it) "raccordo luer-lock con cappuccio di protezione per linee medicali di infusione-trasfusione."
TR199600498A2 (tr) S(+)-ibuprofen'in oral formülasyonlari.
HK1018396A1 (en) Delivery system of an active agent.
PL300194A1 (en) Interferon conjugate, method of obtaining same and pharmaceutical composition containing it
DK0886474T4 (da) Karameller indeholdende et södemiddel
TR199600499A2 (tr) S(+)-Etodolak'in oral formülasyonlari.
ZA9811445B (en) Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions.
ZA9510924B (en) Soluble 2-chloro-2'-deoxyadenosine formulations
HK1029928A1 (en) Pharmaceutical compositions of peptides having lowsolubility in physiological medium.
JO1908B1 (en) Static compounds of 2-chloro-2-dioxin adenosine
ZA949874B (en) B3-adrenergic agents, benzodioxole dicarboxylates and their use in pharmaceutical compositions.
ZA974366B (en) Potassium, sodium and tris oxaprozin salt pharmaceutical formulations.
CA2208241A1 (en) Stable solutions of 2-chloro-2'-deoxyadenosine formulations
ES2178200T3 (es) Conservante para lentes de contacto, solido y soluble en agua.
JO1907B1 (en) Dissolved compounds of 2-chloro-2-dioxin adenosine
AP2000001946A0 (en) Form V1 5,6-Dichloro-2-(isopropylamino)-1-(B-L-Ribofuranosyl)-1H- benzimidazole.
日合弘 et al. Induction of B-cell Lymphoma in BALB/c nude mice with an ecotropic, B-tropic helper virus present in the MAIDS virus stock.